首页> 外文期刊>Photodiagnosis and Photodynamic Therapy >Treatment of superficial basal cell carcinoma with photodynamic therapy. Observational study in 22 patients with 5-aminolaevulinic acid and methyl aminolaevulinate
【24h】

Treatment of superficial basal cell carcinoma with photodynamic therapy. Observational study in 22 patients with 5-aminolaevulinic acid and methyl aminolaevulinate

机译:光动力疗法治疗浅表基底细胞癌。 5-氨基戊酸和甲基氨基戊酸甲酯22例观察研究

获取原文
获取原文并翻译 | 示例
       

摘要

Background: There is limited literature on efficacy in 5-aminolaevulinic acid (BF-200 ALA) and methyl-5-aminolaevulinate (MAL) for superficial basal cell carcinoma (sBCC).Aims: To investigate the efficacy and safety of PDT in sBCC.Methods: Analytical observational study between January 2014 and January 2017. Follow-up at 12, 24 and 52 weeks. Lesions were treated with one BF-200 ALA-PDT or MAL-PDT cycle of two sessions in one week. A second treatment cycle, with the same photosensitizer precursor, was performed in cases of clinical persistence at 12 weeks.Results: A total of 22 patients (30 lesions) were enrolled in the study. By sex, 13 men and 9 women. Average age of 72,14 years. In the 12-month follow-up 15/16 lesions were resolved (93,75%) after one or two BF-200 ALA-PDT cycle and 7/14 lesions (50%) after one or two MAL-PDT cycles. In most patients, tolerance to the therapy was good or regular, with no differences between the two groups. No long-term adverse effects were reported.Limitations: The observational nature and the low number of patients.Conclusion: PDT is a safe and non-invasive treatment option in sBCC. Our results suggest a better response with BF-200 ALA-PDT over MAL-PDT, at 12 months of follow-up.
机译:背景:关于5-氨基戊酸(BF-200 ALA)和5-氨基戊酸甲酯(MAL)用于浅表性基底细胞癌(sBCC)的疗效研究文献很少。目的:研究PDT在sBCC中的疗效和安全性。方法:2014年1月至2017年1月之间的分析性观察研究。在第12、24和52周进行随访。一周内用两个疗程的BF-200 ALA-PDT或MAL-PDT周期治疗病变。在临床持续12周的情况下,使用相同的光敏剂前体进行第二个治疗周期。结果:总共22例患者(30个病灶)被纳入研究。按性别分,男13名,女9名。平均年龄为72.14岁。在12个月的随访中,经过一两次BF-200 ALA-PDT循环后,有15/16处病变得以解决(93.75%),经过一两次MAL-PDT循环后,有7/14处病变(50%)得到了解决。在大多数患者中,对治疗的耐受性良好或有规律,两组之间无差异。局限性:观察性和患者人数少。结论:PDT是sBCC中一种安全且无创的治疗选择。我们的结果表明,在随访的12个月中,BF-200 ALA-PDT优于MAL-PDT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号